The company specializes in developing and selling broad-spectrum cancer immunotherapy products that leverage the patient's immune system to eradicate cancer cells. Myst Therapeutics focuses on adoptive cell therapy, utilizing T cells from tumors and peripheral blood to target a wide range of cancer mutations. Recently, the company was acquired by Turnstone Biologics Corp., another biotech firm dedicated to advancing T-cell therapies for solid tumors. For more information about Turnstone Biologics, please visit their LinkedIn page: https://www.linkedin.com/company/turnstone-biologics/